Retina/Vitreous News

In this Healio Video Perspective from the ASRS meeting, Diana V. Do, MD, FASRS, of Byers Eye Institute discusses data from the PHOTON trial investigating aflibercept 8 mg and aflibercept 2 mg for the treatment of diabetic macular edema.

In this Healio Video Perspective from the ASRS annual meeting, Dilraj Grewal, MD, FASRS, discusses eyes that developed macular neovascularization in the GATHER trials.

Use of a DPP-IV inhibitor, SGLT2 inhibitor or GLP-1 receptor agonist does not increase risk for diabetic macular edema among adults with type 2 diabetes and diabetic retinopathy, according to study data.

A form of dropless vitrectomy helped control intraocular inflammation and prevent infection after surgery for vitreous hemorrhage secondary to proliferative diabetic retinopathy, according to a study.

In this Healio Video Perspective from the ASRS meeting, Christina Y. Weng, MD, MBA, FASRS, of Baylor College of Medicine in Houston discusses 96-week safety and tolerability data for aflibercept 8 mg.

Eluminex Biosciences has dosed the first patient in the phase 1b LOTUS trial, which will evaluate three dose levels of the trispecific fusion antibody EB-105 in patients with diabetic macular edema.

In a paper recently published in Retina, an expert panel of retina specialists provided guidance on suprachoroidal space injection.

PARK CITY, Utah — Suprachoroidal drug delivery for uveitic macular edema provides durable effects in real-world settings, matching those of phase 3 clinical trials, according to a speaker at Clinical Trials at the Summit.

The first analysis of real-world outcomes in patients with neovascular age-related macular degeneration treated with pegcetacoplan for geographic atrophy demonstrated similar safety seen in clinical trials, according to a study.

PARK CITY, Utah — APX3330, an investigational systemic treatment for diabetic retinopathy, showed encouraging outcomes in the phase 2 ZETA-1 trial, paving the way to phase 3.